Text Size

Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01096667
First received: March 26, 2010
Last updated: April 10, 2013
Last verified: April 2013
History of Changes
  Purpose

B1521004 is designed to study how safe and how effective is an investigational drug, PF-04971729, in people with type 2 diabetes and hypertension. Patients in the study will receive 1 of 5 treatments for 1 month including 1 treatment with an approved drug - hydrochlorothiazide.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Hypertension
 Drug: Placebo
Drug: 1 mg PF-04971729
Drug: 5 mg PF-04971729
Drug: 25 mg PF-04971729
Drug: 12.5mg HCTZ
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Placebo-adjusted, change from baseline on average, 24 hour systolic blood pressure (SBP) on Day 28 assessed using 24 hour ambulatory blood pressure monitoring (ABPM) [ Time Frame: 28 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Placebo-adjusted, change from baseline on average, daytime, night time and 24-hour diastolic blood pressure (DBP), and pulse rate on Day 28 using 24 hour ABPM [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Placebo-adjusted, change from baseline on average daytime, night time SBP using 24 hour ABPM [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Placebo-adjusted, change from baseline in trough SBP, DBP and pulse rate using automated device [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Placebo-adjusted, change from baseline on 24 hour urinary glucose excretion on Day 28 [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Placebo adjusted, change from baseline in fasting plasma glucose [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Placebo-adjusted, change from baseline on average, daytime, night time and 24 hour SBP, DBP, pulse rate on Day 28 using 24 hour ABPM [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
  • Assessment of clinical safety-related laboratory tests, 12 lead electrocardiograms (ECG), adverse events/serious adverse events including urinary tract and genital fungal infections, hypo- and hyper- glycemia as well as hypo- and hyper tension [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]

Enrollment: 195
Study Start Date: May 2010
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo for PF-04971729 and HCTZ
 Drug: Placebo
Pills (n=3), 0 mg, once daily x 28-days
Experimental: 1 mg PF-04971729
1 mg PF-04971729
 Drug: 1 mg PF-04971729
pill (n=1), 1 mg strength + pills (n=2), 0 mg, all once daily x 28-days
Experimental: 5 mg PF-04971729
5 mg PF-04971729
 Drug: 5 mg PF-04971729
pill (n=1), 5 mg strength + pills (n=2), 0 mg, all once daily x 28-days
Experimental: 25 mg PF-04971729
25 mg PF-04971729
 Drug: 25 mg PF-04971729
pill (n=1), 25 mg strength + pills (n=2), 0 mg, all once daily x 28-days
Active Comparator: 12.5mg HCTZ
12.5mg hydrochlorothiazide (HCTZ)
 Drug: 12.5mg HCTZ
pill (n=1), 12.5 mg strength + pills (n=2), 0 mg, all once daily x 28-days

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with type 2 diabetes and hypertension
  • Medically stable
  • On at least 1 (and up to 2) oral diabetes drugs
  • And up to 2 medicines for blood pressure control

Exclusion Criteria:

  • Patients with type 1 diabetes
  • Heart attack
  • Stroke
  • Uncontrolled blood pressure
  • Significant kidney disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01096667

  Show 40 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01096667     History of Changes
Other Study ID Numbers: B1521004
Study First Received: March 26, 2010
Last Updated: April 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
type 2 diabetes
hypertension
ambulatory blood pressure monitoring

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Hydrochlorothiazide
Diuretics
 Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 17, 2013